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Abstract
Purpose: Aim of this study was to evaluate the distribu-
tion of persistent mesorectal lymph node metastases on
restaging MRI in patients with a good or complete
response of their primary tumor (ypT0-2) after CRT for
locally advanced rectal cancer.
Methods: Two hundred and twenty eight locally ad-
vanced rectal cancer patients underwent CRT, which
resulted in a good response (downstaging to yT0-2) in
144 patients. Forty-nine patients were excluded (no
surgery/insufficient follow-up or lacking lesion-by-lesion
histology results). This resulted in a final study group of
95 yT0-2 patients. For the patients with a yN+-status,
a detailed lesion-by-lesion comparison between restaging
MRI and histology was performed to evaluate the
characteristics and distribution of the individual
N+-nodes.
Results: 7/95 patients (7%) had a yT0-2N+ status (11/
880 (1%) N+ nodes): no N+ were found below the tumor
level, 55% of the N+ nodes were located at the level of
the tumor, and 45% proximal to the tumor (at a median
distance of 1.4 cm above the tumor level). In axial plane,
82% of the nodes were located at the ipsilateral circum-
ference of the tumor, at a median distance of 0.9 cm from
the tumor/rectal wall.
Conclusions: The incidence of persistent metastatic
mesorectal nodes after CRT in patients with a good
tumor response after CRT is very low. No N+ nodes are
found below the tumor level. All N+ nodes are located at
the level of or proximal to the primary tumor, of which
the majority very close to the tumor/lumen.
Key words: Rectal cancer—MRI—Lymph node
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The staging of lymph nodes remains one of the main
diagnostic challenges in the imaging evaluation of rectal
cancer. At primary staging, the presence of suspected
metastatic lymph nodes can help determine the necessity
for neoadjuvant (chemo)radiation treatment (CRT). In
patients undergoing neoadjuvant CRT, it has become
standard practice in a growing number of centers to
perform a restaging MRI 6–8 weeks after CRT to assess
the degree of downsizing and downstaging of the pri-
mary tumor as well as the nodes. While it is not yet
routine practice, organ-preserving treatment (a local
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excision or ‘wait and see’) is increasingly considered as a
potential alternative to standard resection for the very
good or complete responding patients after CRT. The
ﬁrst observational trials of ‘wait-and-see’ after CRT have
shown promising results regarding long-term survival [1]
Habr-Gama et al. recently showed a local recurrence rate
of 31% and an overall survival of 91% for patients
undergoing a ‘wait-and-see’ policy, with a median fol-
low-up of 5 years [2]. Maas et al. and Smith et al. re-
ported similar results when using strict selection criteria,
albeit in smaller patient cohorts [3, 4]. Other groups have
performed a local excision (transanal endoscopic micro-
surgery, TEM) after CRT in patients clinically suspected
of having responded well with a small (ycT1-2) residual
tumor. For example, Lezoche et al. showed in a ran-
domized trial that a TEM after CRT for patients with a
ycT2N0 tumor resulted in a prognostic outcome com-
parable to TME after CRT [5]. When considering TEM
or wait-and-see, an accurate patient selection is an
important prerequisite.
Digital rectal examination and endoscopy (with
biopsies) are currently the tools most commonly used to
assess the local tumor response, because they can eval-
uate the intraluminal side of the bowel wall. Combined
with MRI, these tools have been shown to be highly
accurate to identify patients with a complete regression
of their primary tumor [6]. DRE and endoscopy are,
however, not helpful to assess the mesorectal compart-
ment outside the bowel wall and the nodes within. For
this purpose, a restaging MRI could have a particularly
beneficial role. Even with a good or complete tumor re-
sponse the risk for persistent nodal disease is known to
be approximately 5%–16% [7–10]. Since the mesorectal
compartment—and thus all embedded lymph
nodes—remains in situ with both a local excision and
‘wait-and-see’-policy, it is important to identify these
nodes. Moreover, knowledge on the distribution of
remaining mesorectal nodal metastases could help in
understanding which specific areas are at risk to harbor
remaining positive nodes and are thus at risk for a nodal
tumor regrowth.
The aim of our study is to evaluate the presence
and distribution of mesorectal lymph node metastases
after neoadjuvant chemoradiotherapy in patients who
have responded with a complete or near complete
response of their primary tumor, i.e., potential can-




All consecutive locally advanced rectal cancer patients
treated with neoadjuvant chemoradiotherapy between
January 2006 and November 2013 were considered for
inclusion in this retrospective study. The study was
conducted as part of ongoing clinical studies on nodal
imaging, which were approved by the local institutional
review board and for which all patients provided written
informed consent. Inclusion criteria consisted of (a)
biopsy proven rectal cancer with an inferior tumor
margin less than 15 cm from the anal verge, (b) age
>18 years, (c) long course neoadjuvant treatment, (d)
evidence of a good or complete (yT0-2) response of the
primary rectal tumor after CRT (either histopathologi-
cally proven after TME/TEM or—in case of ‘‘wait-and-
see’’ treatment—conﬁrmed by at least 2 years FU and
biopsy results without evidence of residual/recurrent tu-
mor or metastatic nodes), and (e) availability of a lesion-
by-lesion comparison of lymph nodes between MRI and
histology in the patients undergoing resection. Exclusion
criteria were (a) pregnancy, (b) non-resectable disease,
and (c) contraindications for MRI. In total, 228 con-
secutive patients underwent long course preoperative
chemoradiotherapy. The routine neoadjuvant treatment
schedule consisted of 50.4 Gy radiation combined with
2 9 825 mg/m2/day capecitabine. Of these patients, 144/
228 (63.2%) showed a good or complete response of their
primary tumor (yT0-2). Forty-nine were excluded for the
following reasons: 42 were treated with organ preserva-
tion but did not reach a follow-up period of at least
2 years at the time of writing, 5 were inoperable due to
synchronous metastatic disease, and in 2 patients a le-
sion-by-lesion MR-histological comparison could not be
performed. This left a total study population of 95 pa-
tients (62 male, 33 female; median age 69 years, range
35–88) with a complete or good tumor response (yT0-2)
after CRT.
MR imaging
All patients underwent a primary staging MRI and a
second, restaging MRI routinely performed 6–8 weeks
after completion of the preoperative CRT. Patients did
not receive bowel preparation. To reduce bowel motility,
20 mg of scopolamine butylbromide (Buscopan, Boeh-
ringer Ingelheim, Germany) was administered intra-
venously just before the MRI, either in case of
anticipated bowel movement artifacts on the sagittal
planning scan (during the ﬁrst half of the study period)
or routinely (during the second half of the study period).
Imaging was performed at a 1.5T MR unit (Intera or
Intera Achieva; Philips Medical Systems, Best, The
Netherlands) using a phased array body coil. The stan-
dard clinical MR protocol consisted of 2D T2-weighted
fast spin echo sequences in 3 planes (sagittal, axial, and
coronal). Additionally, a 3DT1-weighted gradient echo
sequence (TR/TE 9.8/4.6 ms, 15 ﬂip angle, 1 NSA,
1.15 9 1.15 9 1.00 mm voxel size, and 6.30 min acqui-
sition time) was acquired to optimally depict the lymph
nodes. The latter sequence was used for nodal evaluation
in the current study.
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Image evaluation
An experienced pelvic MR reader (LAH) evaluated each
MRI and performed a careful search for all visible lymph
nodes within the mesorectal compartment on the 3D-
T1weighted GRE sequence. Extramesorectal (lateral)
lymph nodes were not taken into account. Multiplanar
reformatting of the images was performed to accurately
determine the position of each visible lymph node with




Similar to the methodology described in previous re-
ports, all nodes visualized on the 3DT1-weighted MRI
were drawn on an anatomical map [11, 12]. In the pa-
tients undergoing resection, this map was used as a
template to ensure accurate node-by-node matching with
histopathology. The TME resection specimens were
sectioned transversely each 5 mm, perpendicular to the
tumor axis. A dedicated pathologist carefully searched
for lymph nodes in each section. Each node was placed in
a marked individual tray and multiple histological sec-
tions were analyzed for each node (for small 1–2 mm
nodes only one section was assessed). At microscopic
examination, the pathologist reported each node as be-
nign or malignant. For each malignant node, the volume
of metastatic disease within the node (%) was estimated.
In the patients undergoing a local excision or a ‘wait-
and-see’ policy with a recurrence-free follow-up period of
2 years, all nodes visualized on MRI were considered
benign lymph nodes.
Localization of lymph nodes
For each individual lymph node depicted on the 3D-
T1W GRE sequence (including MPR reformatting), the
following parameters were recorded: [1] N+ or N- node
(based on histopathology and/or long-term FU), [2] size
(short axis diameter in mm), [3] position relative to the
primary tumor as determined on sagittal or coronal
reconstructed plane (i.e., at the level of the tumor, or
9mm distal or proximal to the primary tumor), [4] dis-
tance from the primary tumor in axial plane (mm), [5]
location (…o’clock) of the lymph node in axial plane/
supine position (with 12 o’clock being anterior and 3
o’clock being left lateral location). The nodes localization
procedure is illustrated in Fig. 1.
Results
Patient characteristics
Patient characteristics are provided in detail in Table 1.
Of the 95 study patients, 61 underwent TME and 34
underwent organ-preserving treatment (4 TEM and 30 a
wait-and-see policy) with >2 year follow-up. Fifty-four
patients had a yT0, 10 a yT1, and 31 a yT2 status. The
overall incidence of yT0-2N+ disease was 7/95 (7.4%): 3/
54 (5.6%) in patients with a complete tumor response
(yT0) and 4/41 (9.8%) in patients with a good tumor
response (yT1-2). In the 61 patients who underwent a
total mesorectal excision, a total number of 671 nodes
Fig. 1. Multiplanar reformatting (MPR) view of the 3D-
T1weighted GRE images of a patient with a good tumor re-
sponse after CRT, with (A) an overview of the MPR window,
(B) the reconstructed axial view, and (C) the reconstructed
sagittal view. The position of each visible lymph node (arrow)
with regard to the tumor bed (asterisk) was measured in
three-dimensional planes.
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was harvested from the mesorectal fat at histopathology
(median 12 nodes per patient, range 1–25, 660 benign, 11
malignant). In addition, 209 nodes were observed on
restaging MRI in the patients undergoing TEM or wait-
and see with >2 year FU, and these nodes were all
considered benign. Hence, the total number of metastatic
nodes after CRT was 11/880 (1.3%).
Characteristics of the N+ nodes
The 11 metastatic nodes were observed in 7 patients.
Median size (as measured on MRI) of the non-metastatic
nodes was 3 mm (range 1–19 mm), compared to 6 mm
(range 3–12 mm) for the metastatic nodes. In the meta-
static nodes, the total tumor volume (viable tumor
cells ± necrosis) within the node was <25% in 5 nodes
(46%), 25%–50% in 1 node (9%), 50%–75% in 3 nodes
(27%), and>75% in 2 nodes (18%). Figures 2 and 3 both
show an example of a micrometastatic and macrometa-
static lymph node, respectively.
Distribution of lymph nodes
The location of the metastatic lymph nodes in relation to
the primary rectal tumor is schematically illustrated in
Fig. 4. Further details on the characteristics and location
of the individual metastatic lymph nodes are provided in
Table 2. No metastatic nodes were found distal to the
tumor. Fifty-five per cent of the metastatic nodes were
located at the level of the (former) rectal tumor; the other
45% were located proximal to the tumor site at a median
distance of 14 mm (10–29 mm) from the most proximal
tumor margin. In axial plane, 82% of the metastatic
nodes were located at the ipsilateral circumference of the
tumor bed and 18% contralateral. The median distance
of the metastatic nodes to the tumor bed in axial plane
was 9 mm (0–22 mm). Of the non-metastatic nodes 5.4%
was located distal to the tumor site, 18.5% was located at
the level of the tumor, and 76.1% was located proximal
to the tumor.
Discussion
The results of our study show that the overall incidence
of persistent positive lymph nodes in patients with locally
advanced rectal tumors that have responded well and
downstaged to yT0-2 after preoperative CRT is 7%; 6%
for the complete responders (T0) and 10% for the pa-
tients with a small T1-2 residual tumor. No metastatic
nodes were found distal to the tumor level; all persistent
metastatic nodes were located at the level or proximal to
the (former) tumor bed. Furthermore, the metastatic
nodes were mainly located in the proximity of the tumor
at the ipsilateral circumference.
Ex-vivo cadaver studies have shown that the overall
anatomical presence of lymph nodes (in non-oncological
patients) is low in the distal mesorectum compared with
their presence in the proximal two-thirds of the
mesorectum [13]. Furthermore, in patients with rectal
cancer, Engelen et al. showed that on primary staging
MRI only 10% of the non-metastatic nodes and only 2%
of the metastatic nodes were located below the tumor
bed, while all other metastatic nodes were located at the
same height (66%) or proximal to the tumor (32%) [14].
Koh and colleagues reported similar numbers. They
found in a small group of 16 patients that almost all
nodes (98%, both benign and malignant) on primary
staging MRI were located at the level of or within 5 cm
proximal to the tumor [15]. Similarly, in a subsequent
small study by the same group on restaging MRI after
CRT, it was found that no nodes remained after CRT
distal to the tumor [16]. Sprenger et al. confirmed this
observation by showing that—after CRT—only 9% of
the nodes, regardless of their histopathological features,
was found distal to the tumor [17]. Our current study in a
significantly larger patient cohort confirmed previous
literature: all persistent metastatic nodes were located at
Table 1. Patient characteristics
Features Number of







Tumor height on MRI (measured
in cm from anorectal verge)
Distal (up to 4 cm) 72 (75.8%)
Mid-rectal (from >4 to 8 cm) 19 (20.0%)
Proximal (from >8 to 12 cm) 4 (4.2%)











Total number of nodes*
Benign 869
Malignant 11
Number of nodes per patient
Median 12
Range 1–25




At the level of the tumor 161 (18.5%)
Distal 47 (5.4%)
Proximal 661 (76.1%)
* 671/880 (76.3%) nodes were confirmed histopathologically, the other
209 nodes (in patients undergoing TEM or wait-and-see) were detected
at MRI and confirmed to be negative by >2 year FU without recur-
rence
** Nodal size was measured on MRI
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the tumor level or above and no metastatic nodes oc-
curred distal to the tumor level. Similarly, of the non-
metastatic nodes only 5.4% was located below the tumor
level, while the other non-metastatic nodes were all sit-
uated at or above the tumor level.
This study speciﬁcally focused on the subgroup of
patients who showed a complete or near complete re-
sponse of their primary tumor after CRT. These patients
are of particular clinical interest, as they constitute the
subgroup that might be considered for organ-preserving
treatments. An important topic of ongoing debate is how
to select the right patients for organ-preserving treat-
ments without putting the patient at risk for
undertreatment and consequently tumor regrowth. A
prerequisite for organ preservation is that the primary
tumor shows a clinical complete or near complete re-
sponse and all initially suspicious nodes are sterilized. In
a recent report, Perez and co-authors reported on
changes in nodal size after CRT in patients with a good
primary tumor response [18]. They evaluated a total
Fig. 3. Example of a macro-metastasis: A 3D-T1W GRE images showed a 4 mm node (arrow). B At histology, a large part of
the node was necrotic. The necrotic cells were encircled by abundant viable tumor cells (arrowheads).
Fig. 2. Example of a micrometastasis: A 3D-T1W GRE images showed a small (3 mm) node (arrow). B At histology, a small
area of necrosis was present in the center of this node (arrow) and only a small cluster of viable metastatic tumor cells (circle).
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number of 201 nodes in 31 patients with a ypT0-2 status
after CRT and found that metastatic foci were still pre-
sent in 12/201 (6%) nodes, similar to the observed small
number of metastatic nodes (1%; 11/880) in our current
report. At the optimal size cut off of ‡4.5 mm, the
specificity for assessment of ypN+ disease was high
(95%), at the expense of a sensitivity of only 42%. Al-
though it is generally known that size is a poor predictor
for rectal cancer lymph nodes, some studies have sug-
gested that size criteria work better in the restaging set-
ting because nodes are smaller in size due to downsizing
as a result of the irradiation. Nodes that remain large
after CRT are thus more likely to be malignant. Never-
theless, accuracies for nodal restaging with MRI showed
a wide range from 67% to 90%, because of the difficulties
in detecting and assessing small sized nodes [12, 16, 19–
23].
Apart from the identiﬁcation of positive nodes after
CRT, information on the distribution of these nodes
could have clinical value. First, it is important to know
that no metastatic nodes remain distal to the tumor site
to determine the distal resection margin in case of a low
anterior resection. When considering a local excision,
some authors have suggested that nodes in the proximity
of the tumor remnant/rectal wall may be excised with an
extended local excision [24]. Furthermore, information
on the distribution of remaining positive nodes after
CRT could hypothetically be used to plan a targeted
boost of radiotherapy specifically focused on sterilizing
these nodes. Finally, the nodal distribution after preop-
erative CRT has been suggested to withhold prognostic
information regarding the risk of distant metastatic tu-
moral spread [25] as well as overall survival [17]. Leibold
et al. reported that patients with proximal lymph node
Table 2. Overview and characteristics of metastatic lymph nodes after CRT
Patient Tumor Node Nodal size
on MRI (mm)
Volume of
metastasis at PA (%)





1 ypT0N1 Mid 1 6 25–50 1 Ipsilateral 0
2 ypT0N1 Distal 2 8 >75 2 Ipsilateral 0
3 ypT0N1 Mid 3 7 <25 9 Ipsilateral 0
4 ypT2N1 Distal 4 8 50–75 0 Ipsilateral 29
5 ypT2N1 Distal 5 12 <25 2 Ipsilateral 18
6 ypT2N1 Distal 6 6 <25 22 Ipsilateral 0
7 4 <25 9 Contralateral 14
8 3 <25 13 Contralateral 14
7 ypT2N1 Distal 9 5 50–75 6 Ipsilateral 0
10 6 50–75 10 Ipsilateral 0
11 3 >75 10 Ipsilateral 10
Mean 6 8 8
SD 3 6 10
Fig. 4. Schematic overview of the location of persistent
metastatic lymph nodes after CRT. A Distribution of the nodes
relative to the residual tumor bed in sagittal plane (proximal,
peritumoral or distal). B Distribution of the nodes relative to
the residual tumor bed in axial plane (ipsilateral or contralat-
eral circumference).
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metastases (i.e., along major supplying blood vessels)
had a significantly higher risk for distant metastases
compared with patients without proximal node involve-
ment (46% vs. 25%, p < 0.001) [25] Similarly, Sprenger
and colleagues found that patients with metastases in
proximal lymph nodes after CRT had significantly im-
paired cancer-specific survival compared to patients with
peritumoral nodal metastases only (p < 0.05) [17].
Interestingly, about half of the persistent metastatic
nodes after CRT in our study contained only small
clusters or even single-tumoral cells. One can argue
whether these micrometastases impact prognosis and
consequently whether it is imperative to recognize these
micrometastases since they might progressively response
and sterilize at longer follow-up as a late effect of
(chemo)radiation [26–31]. This is a topic that will need to
be addressed by further studies.
There were some limitations to our study design.
First, the total number of individual nodal metastases
and N+ patients in our study cohort is limited, which is
inherent to the specific selection of patients with a good
tumor response in whom the risk for nodal metastases is
known to be low. Second, 34 patients did not undergo
TME surgery, but an organ-preserving treatment, due to
which histopathological validation of the nodes was not
available. However, these patients remained recurrence
free for >2 years, which can serve as a surrogate end-
point for a yN0 status. Finally, this study focused
specifically on nodes within the mesorectal compartment.
As such, extramesorectal (lateral) pelvic lymph nodes
were not taken into account.
In conclusion, our study demonstrates that persistent
metastatic lymph nodes in the mesorectum are rare in
patients with locally advanced rectal cancer who undergo
a complete or near complete response after CRT. The
metastatic nodes that persist after CRT are located at the
level of or proximal to the initial tumor bed and tend to
occur on the ipsilateral circumference of and at close
distance to the tumor. No persistent metastatic nodes are
found below the tumor level. This information may be
valuable for clinical selection and follow-up of patients
who are considered for organ-preserving treatment
strategies after CRT.
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